

Title (en)
ANTIBODIES SPECIFIC TO KDR AND USES THEREOF

Title (de)
ANTIKÖRPER SPEZIFISCH FÜR KDR UND IHRE VERWENDUNGEN

Title (fr)
ANTICORPS SPECIFIQUES AU KDR ET LEURS UTILISATIONS

Publication
EP 1151002 A4 20020502 (EN)

Application
EP 00913280 A 20000128

Priority
• US 0002180 W 20000128
• US 24073699 A 19990129
• US 11772699 P 19990129

Abstract (en)
[origin: WO0044777A1] The invention provides an immunoglobulin molecule which binds SI(KDR) with an affinity comparable to human VEGF, and that neutralizes activation of KDR. Immunoglobulin molecules include monovalent single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, antibodies, humanized antibodies and chimerized antibodies. The invention further provides nucleic acid molecules that encode these immunoglobulin molecules. The invention also provides a method of making the immunoglobulin molecules mentioned above. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal with such immunoglobulin molecules.

IPC 1-7
C07K 14/00; **C07K 16/00**; **C07K 16/28**; **C12N 15/11**; **C12N 15/00**; **A61K 39/395**

IPC 8 full level
C12N 15/09 (2006.01); **A61K 39/395** (2006.01); **A61P 7/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 16/28** (2006.01); **C07K 16/46** (2006.01); **C12P 21/02** (2006.01)

CPC (source: EP)
A61P 7/00 (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07K 16/2863** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/622** (2013.01); **C07K 2317/626** (2013.01); **C07K 2319/00** (2013.01)

Citation (search report)
• [A] WO 9116353 A1 19911031 - CORVAS INTERNATIONAL N V [BE]
• [A] WO 9811223 A1 19980319 - SCHERING AG [DE], et al
• [PX] WO 9940118 A1 19990812 - KYOWA HAKKO KOGYO KK [JP], et al
• [PX] WO 9960025 A1 19991125 - KYOWA HAKKO KOGYO KK [JP] & EP 1086705 A1 20010328 - KYOWA HAKKO KOGYO KK [JP]
• [X] ZHU Z ET AL: "Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, no. 15, 1 August 1998 (1998-08-01), pages 3209 - 3214, XP002141908, ISSN: 0008-5472
• [X] WITTE L ET AL: "MONOCLONAL ANTIBODIES TARGETING THE VEGF RECEPTOR-2 (FLK1/KDR) AS AN ANTI-ANGIOGENIC THERAPEUTIC STRATEGY", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 17, no. 2, 1998, pages 155 - 161, XP000940443, ISSN: 0167-7659
• [X] HICKLIN D J ET AL: "MONOCLONAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR (KDR) ANTIBODIES WHICH ARE INHIBITORS OF VEGF BINDING AND ANTAGONISTS OF VEGF-STIMULATED SIGNALING AND GROWTH OF HUMAN ENDOTHELIAL CELLS", PROCEEDINGS OF THE 89TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. NEW ORLEANS, LA, MARCH 28 - APRIL 1, 1998, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: AACR, US, vol. 39, March 1998 (1998-03-01), pages 96, XP000918907
• See references of WO 0044777A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0044777 A1 20000803; AU 3475100 A 20000818; CA 2361553 A1 20000803; CN 1345334 A 20020417; EP 1151002 A1 20011107; EP 1151002 A4 20020502; IL 144578 A0 20020523; JP 2002536968 A 20021105

DOCDB simple family (application)
US 0002180 W 20000128; AU 3475100 A 20000128; CA 2361553 A 20000128; CN 00805856 A 20000128; EP 00913280 A 20000128; IL 14457800 A 20000128; JP 2000596033 A 20000128